TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted anti-tumor T cells by facilitating costimulation
Preprint
- 26 April 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Blockade of the immune checkpoints PD-1 and TIGIT has demonstrated activity in mouse tumor models and human cancer patients. Although these coinhibitory receptors can restrict signaling in CD8+ T cells by regulating their associated costimulatory receptors CD28 and CD226, the functional consequences of combining PD-1 and TIGIT blockade remain poorly characterized. In mouse tumor models, combination blockade elicited CD226-driven clonal expansion of tumor antigen-specific CD8+ T cells. The expanded clones emerged from a population of stem-like cells in draining lymph nodes (dLN), entering the blood as a previously unidentified single-phenotype, multi-clonal population. Upon reaching the tumor, these tumor antigen-specific transiting cells expanded further and differentiated into effector or exhausted T cells, with combination blockade restricting entry into the exhaustion pathway by favoring costimulation. Thus, PD-1 and TIGIT inhibition helps shape the repertoire of tumor-reactive CD8+ T cells in dLN and determines their immunological fate in the tumor to enhance therapeutic benefit. Analysis of clinical trial samples suggests a similar mechanism may also occur in cancer patients.Keywords
All Related Versions
- Version 1, 2024-04-26, Research Square
- Published version: Nature Cancer, 5 (12), 1834.
This publication has 46 references indexed in Scilit:
- CD8+ T cells in the cancer-immunity cycleImmunity, 2023
- Dendritic cells as shepherds of T cell immunity in cancerImmunity, 2023
- Single-cell protein expression profiling resolves circulating and resident memory T cell diversity across tissues and infection contextsImmunity, 2023
- The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1/PD-L1 blockade in draining lymph nodesCell, 2022
- Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responsesImmunity, 2022
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph NodesCancer Cell, 2020
- Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid TumorsCancer Cell, 2019
- Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1−CD8+ Tumor-Infiltrating T CellsImmunity, 2019
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector FunctionCancer Cell, 2014
- The who's who of T‐cell differentiation: Human memory T‐cell subsetsEuropean Journal of Immunology, 2013